HC Wainwright Predicts Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Research analysts at HC Wainwright issued their Q1 2026 EPS estimates for Nuvectis Pharma in a research note issued on Wednesday, February 11th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.29) for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings data on Wednesday, February 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.05).

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuvectis Pharma in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Nuvectis Pharma Price Performance

Shares of Nuvectis Pharma stock opened at $8.78 on Thursday. Nuvectis Pharma has a 1-year low of $5.55 and a 1-year high of $11.52. The business’s fifty day moving average price is $8.10 and its two-hundred day moving average price is $6.93. The company has a market capitalization of $224.86 million, a P/E ratio of -6.41 and a beta of -0.29.

Hedge Funds Weigh In On Nuvectis Pharma

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Nuvectis Pharma by 4.8% in the third quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after buying an additional 31,903 shares during the period. Iridian Asset Management LLC CT raised its position in Nuvectis Pharma by 44.5% in the fourth quarter. Iridian Asset Management LLC CT now owns 586,320 shares of the company’s stock worth $4,427,000 after acquiring an additional 180,699 shares in the last quarter. Baldwin Wealth Partners LLC MA lifted its holdings in Nuvectis Pharma by 11.2% in the 4th quarter. Baldwin Wealth Partners LLC MA now owns 389,625 shares of the company’s stock valued at $2,942,000 after acquiring an additional 39,164 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Nuvectis Pharma by 11.8% during the 4th quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock valued at $2,749,000 after purchasing an additional 38,291 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its position in shares of Nuvectis Pharma by 6.5% during the 4th quarter. Oppenheimer & Co. Inc. now owns 73,566 shares of the company’s stock valued at $555,000 after purchasing an additional 4,500 shares in the last quarter. 96.77% of the stock is currently owned by institutional investors and hedge funds.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.